Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Moderna Inc’s stock clocked out at $63.16, down -1.20% from its previous closing price of $63.93. In other words, the price has decreased by -$1.20 from its previous closing price. On the day, 4.09 million shares were traded. MRNA stock price reached its highest trading level at $63.69 during the session, while it also had its lowest trading level at $62.58.
Ratios:
To gain a deeper understanding of MRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 4.09. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
On September 13, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $88 to $70.
Jefferies Downgraded its Buy to Hold on September 13, 2024, whereas the target price for the stock was revised from $120 to $65.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 09 ’24 when Klinger Shannon Thyme sold 551 shares for $73.57 per share. The transaction valued at 40,539 led to the insider holds 18,154 shares of the business.
Klinger Shannon Thyme bought 551 shares of MRNA for $40,539 on Sep 09 ’24. On Sep 03 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 114 shares for $76.99 each. As a result, the insider received 8,777 and left with 17,566 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 24278452224 and an Enterprise Value of 17059452928. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.82 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 3.378 whereas that against EBITDA is -4.154.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is -23.77%, while the 200-Day Moving Average is calculated to be -40.06%.
Shares Statistics:
It appears that MRNA traded 4.57M shares on average per day over the past three months and 5585530 shares per day over the past ten days. A total of 382.00M shares are outstanding, with a floating share count of 342.77M. Insiders hold about 10.83% of the company’s shares, while institutions hold 67.98% stake in the company. Shares short for MRNA as of 1726185600 were 27613114 with a Short Ratio of 6.05, compared to 1723680000 on 25003118. Therefore, it implies a Short% of Shares Outstanding of 27613114 and a Short% of Float of 9.45.
